Transmedics Group Osake

Transmedics Group EBITDA

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Transmedics Group (TMDX) 4.8.2026 päivämäärällä on 108,58 M USD. Edellisenä vuonna EBITDA (Tulos ennen korkoja, veroja ja poistoja) oli 37,70 M USD — muutos 188,05 % (korkeampi).

EBITDA

108,58 MUSD

YoY

188,05%

Viimeksi päivitetty:

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Transmedics Group on 2026 108,58 M USD. EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Transmedics Group oli 2025 37,70 M USD. Se laskee 188,05% korkeampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Transmedics Group Osakeanalyysi

Mitä Transmedics Group tekee? Transmedics Group Inc is a company dedicated to the development and manufacturing of medical devices for organ transplantation. The company was founded in 1998 and is headquartered in Andover, Massachusetts, USA. Transmedics' business model is based on offering a unique and innovative technology for organ preservation during transport from donor to recipient. The patented Organ Care System (OCS) platform includes a range of state-of-the-art medical devices specifically designed for organ transport. Transmedics' Organ Care System includes three main devices: OCS Heart, OCS Lung, and OCS Liver. Each device is tailored for organ preparation and transport, providing individualized support based on the specific requirements of each organ and different transfer protocols. The OCS technology uses hypothermic (cold) perfusion to preserve the organ during transport. By continuously monitoring and supporting the organ's physiological functions, the OCS system can improve the survival rate of donor organs while reducing the time spent outside the body. Transmedics also offers comprehensive services, including the availability of OCS devices and qualified personnel to provide support throughout the transplantation process. Transmedics' customers include leading transplant centers and hospitals worldwide. The company works closely with these customers to ensure that its OCS devices meet the specific requirements of each transplantation program and help them achieve more successful transplantations. Transmedics' history is marked by a passion for improving transplantation medicine and saving lives through the provision of advanced technologies and solutions. The company has made significant progress in recent years and has experienced strong growth in all areas. Transmedics has also received a number of awards and recognition for its commitment to improving transplantation medicine. For example, in 2020, the company received the Red Herring Top 100 Global Award and was recognized for the seventh consecutive year as one of the fastest-growing companies by Deloitte. Overall, Transmedics is a leading provider of innovative medical devices for transplantation medicine. Through its organic technology and comprehensive service, the company supports transplant centers and hospitals worldwide in performing more successful transplantations and saving patients' lives. Transmedics Group on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Transmedics Group osakkeesta

Yhtiön Transmedics Group EBITDA (Tulos ennen korkoja, veroja ja poistoja) on 108,58 M USD vuonna 2026.

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Transmedics Group muuttui arvosta 37,70 M USD arvoon 108,58 M USD, mikä edustaa 188,05 % muutosta. Arvo on korkeampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBITDA (Tulos ennen korkoja, veroja ja poistoja) Transmedics Group:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBITDA mittaa operatiivista suorituskykyä ennen rahoitusrakenteen, veroympäristön ja muiden kuin käteispoisto-osuuksien vaikutusta.

EBITDA = EBIT + Poistot

EBITDA (Tulos ennen korkoja, veroja ja poistoja):n USD on sijoittajille tärkeä tekijä. Muutokset tässä tunnusluvussa voivat signaloida parantuvia tai heikentyneitä perustekijöitä, mikä vaikuttaa suoraan osakekurssiin. Eulerpoolissa voit seurata EBITDA (Tulos ennen korkoja, veroja ja poistoja):n Transmedics Group historiallisesti ja reaaliajassa.

Access this data via the Eulerpool API

Tuloslaskelma — Transmedics Group

Kaikki tunnusluvut — Transmedics Group